Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 6, 2004, Pages 931-939

  Corral, J ^c,d   Huntington, J A ^b   Gonzalez Conejero R ^c   Mushunje, A ^b   Navarro, M ^a   Marco, P ^a   Vicente, V ^c   Carrell, R W ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF MURCIA   (Spain)

^d HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

Author keywords

Antithrombin; Conformation; Serpin; Thrombosis

Indexed keywords

ANTITHROMBIN; DIMER; DISULFIDE; HEPARIN; OLIGOMER;

ADOLESCENT; ADULT; AFFINITY CHROMATOGRAPHY; AGED; ARTICLE; BIOCHEMISTRY; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIMERIZATION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FREQUENCY ANALYSIS; GEL FILTRATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; INFECTION; MALE; MISSENSE MUTATION; PREGNANCY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; VEIN THROMBOSIS;

ADULT; AGED; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; DIMERIZATION; DISULFIDES; DNA MUTATIONAL ANALYSIS; FAMILY HEALTH; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PEDIGREE; PROTEIN CONFORMATION; SERPINS; SPAIN; VENOUS THROMBOSIS;

EID: 13244295561     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00749.x     Document Type: Article

References (29)

1. Bayton T, Lane D. Antithrombin Mutation Data Base. Department of Haematology, Imperial College Faculty of Medicine, Charing Cross Hospital Campus, London, UK, 2003. http://www.med.ic.ac.uk/divisions/7/antithrombin/
2. Carrell RW, Lomas DA. Conformational disease. Lancet 1997; 350: 134-8.
3. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-6.
4. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency. A model for conformational diseases. N Engl J Med 2002; 346: 45-53.
5. Whisstock JC, Skinner R, Carrell RW, Lesk AM. Conformational changes in serpins. I. The native and cleaved conformations of alpha(1)-antitrypsin. J Mol Biol 2000; 296: 685-99.
6. Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet 2002; 3: 759-68.
7. Okajima K, Abe H, Maeda S, Motomura M, Tsujihata M, Nagataki S, Okabe H, Takatsuki K. Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis. Blood 1993; 5: 1300-5.
8. McKay EJ. A simple two-step procedure for the isolation of antithrombin III from biological fluids. Thromb Res 1981; 21: 375-82.
9. Beauchamp NJ, Pike RN, Daly M, Butler L, Makris M, Dafforn TR, Zhou A, Fitton HL, Preston FE, Peake IR, Carrell RW. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood 1998; 92: 2696-706.
10. Carrell RW, Huntington JA, Mushunje A, Zhou A. The conformational basis of thrombosis. Thromb Haemost 2001; 86: 14-22.
11. Himpel S, Panzer P, Eirmbter K, Czajkowska H, Sayed M, Packman LC, Blundell T, Kentrup H, Grotzinger J, Joost HG, Becker W. Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem J 2001; 359 497-505.
12. Fitton HL, Pike RN, Carrell RW, Chang WS. Mechanisms of antithrombin polymerisation and heparin activation probed by the insertion of synthetic reactive loop peptides. Biol Chem 1997; 378: 1059-63.
13. Mahadeva R, Dafforn TR, Carrell RW, Lomas DA. 6-mer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerization. Implications for the prevention of Z alpha(1)-antitrypsin-related cirrhosis. J Biol Chem 2002; 277 6771-4.
14. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998; 54: 905-21.
15. Lane DA, Bayston T, Olds RJ, Fitches AC, Cooper DN, Millar DS, Jochmans K, Perry DJ, Okajima K, Thein SL, Emmerich J. Antithrombin mutation database: 2nd (1997) update. Thromb Haemost 1997; 77 197-211.
16. Millar DS, Wacey AI, Ribando J, Melissari E, Laursen B, Woods P, Kakkar VV, Cooper DN. Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis. Hum Genet 1994; 94: 509-12.
17. Jochmans K, Lissens W, Vervoot R, Peeters S, De Waele M, Liebaers I. Antithrombin-Gly 424 Arg: a novel point mutation responsible for type I antithrombin deficiency and neonatal thrombosis. Blood 1994; 83: 146-51.
18. The Serpin Database. Serpin Mutations. Cambridge Institute for Medical Research, 2004 http://www.cimr.cam.ac.uk/Serpins/serp_regions/table2.html
19. Belorgey D, Crowther DC, Mahadeva R, Lomas DA. Mutant Neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro. J Biol Chem 2002; 277: 17367-73.
20. Bruce D, Perry DJ, Borg J-Y, Carrell RW, Wardell MR. Thromboembolic diseases due to conformational changes of antithrombin Rouen VI (187 Asn → Asp). J Clin Invest 1994; 94: 2265-74.
21. Picard V, Dautzenberg MD, Villoutreix BO, Orliaguet G, Alhenc-Gelas M, Aiach M. Antithrombin F229L: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosis. Blood 2003; 102: 919-25.
22. Carrell RW, Gooptu B. Conformational changes and disease - serpins, prions and Alzheimer's. Curr Opin Struct Biol 1998; 8 799-809.
23. Marszal E, Danino D, Shrake A. A novel mode of polymerization of alpha-1-proteinase inhibitor. J Biol Chem 2003; 278: 19611-8.
24. Emmerich J, Vidaud D, Alhenc-Gelas M, Chadeuf G, Gouault-Heilmann M, Aillaud MF, Aiach M. Three novel mutations of antithrombin inducing high-molecular-mass compounds. Arterioscler Thromb 1994; 14: 1958-65.
25. Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999; 94: 3388-96.
26. Lindo VS, Kakkar W, Learmonth M, Melissari E, Zappacosta F, Panico M, Morris HR. Antithrombin-TRI (Ala382 to Thr) causing severe thromboembolic tendency undergoes the S-to-R transition and is associated with a plasma-inactive high-molecular-weight complex of aggregated antithrombin. Br J Haematol 1995; 89: 589-601.
27. Tanaka Y, Ueda K, Ozawa T, Sakuragawa N, Yokota S, Sato R, Okamura S, Morita M, Imanaka T. Intracellular accumulation of antithrombin Morioka (C95R), a novel mutation causing type I antithrombin deficiency. J Biol Chem 2002; 277: 51058-67.
28. Parmar JS, Mahadeva R, Reed BJ, Farahi N, Cadwallader KA, Keogan MT, Bilton D, Chilvers ER, Lomas DA. Polymers of alpha(1)-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002; 26: 723-30.
29. O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-8.